Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa

Forest is restructuring its sales representative compensation program to encourage switches from the company's antidepressant Celexa to the follow-on selective serotonin reuptake inhibitor Lexapro

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet